ReviewEndocrine pathology2018
Immunohistochemical Biomarkers in Thyroid Pathology.
Review in Endocrine pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- Influencing factors and prediction model of ultrasound-based false-negative central lymph node metastasis in localized papillary thyroid carcinoma.Gland surgery · 2026Article
- CT Radiomics-Based Machine Learning Model for Predicting Capsular and Neural Invasion in Thyroid Carcinoma: Diagnostic Accuracy Study.JMIR medical informatics · 2026Article
- Encapsulated neoplasms of the thyroid gland.Virchows Archiv : an international journal of pathology · 2026Review
- The actual and future role of molecular tests in thyroid pathology.Virchows Archiv : an international journal of pathology · 2026Review
- Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma: a simplified risk scoring system.Frontiers in endocrinology · 2026Article
- Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review.Frontiers in surgery · 2026Article
- Diagnostic Significance of Trophoblast Cell Surface Antigen-2 Expression in Benign and Malignant Thyroid Lesions.Cureus · 2025Article
- Revisionist history uncovers a simplified molecular-based classification of differentiated thyroid cancer.The Journal of pathology · 2025Review
- Histopathological, Immunohistochemical, Molecular and Genetic Biomarkers in Differentiated Thyroid Cancer.Cancers · 2025Review
- Immunohistochemical profile of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) versus other thyroid follicular lesions.Diagnostic pathology · 2025Article
- Thyroid metastases from breast cancer: a case report and brief literature review.Frontiers in oncology · 2025Article
- Case Report: A rare case of thyroid metastasis from breast cancer.Frontiers in oncology · 2025Article
- Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.Endocrine pathology · 2024Article
- The Spectrum of Endocrine Pathology.Endocrine pathology · 2023Review
- The Unique Importance of Differentiation and Function in Endocrine Neoplasia.Endocrine pathology · 2023Review
- Article
- Thyroid Metastasis from Primary Breast Cancer.Journal of clinical medicine · 2023Review
- Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.Endocrine pathology · 2023Review
- High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas.Endocrine pathology · 2023Review
- Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane.Asian Pacific journal of cancer prevention : APJCP · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of immunohistochemistry to the diagnosis of thyroid lesions has increased as new biomarkers have emerged. In this review, we discuss the biomarkers that are critical for accurate diagnosis, prognosis, and management. Immunohistochemical markers are used to confirm that an unusual tumor in the thyroid is indeed of thyroid origin, either of follicular epithelial or C-cell differentiation; the various mimics include nonthyroidal lesions such as parathyroid tumors, paragangliomas, thymic neoplasms, and metastatic malignancies. Tumors of thyroid follicular epithelial cells can be further subclassified using a number of immunohistochemical biomarkers that can distinguish follicular-derived from C-cell lesions and others that support malignancy in borderline cases. The use of mutation-specific antibodies can distinguish papillary carcinomas harboring a BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.